Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study.
Atezolizumab
Immune checkpoint inhibitors
Nivolumab
Non-small cell lung cancer
Pembrolizumab
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
26
10
2020
accepted:
14
08
2021
pubmed:
17
9
2021
medline:
20
11
2021
entrez:
16
9
2021
Statut:
ppublish
Résumé
As real-world data regarding immunotherapy for non-small cell lung cancer are lacking for Austria, we conducted a retrospective study in six hospitals to present data from real-world practice. Patients with metastatic non-small cell lung cancer were stratified into two groups, either patients with first-line pembrolizumab monotherapy (cohort 1) or patients with second-line nivolumab, pembrolizumab or atezolizumab monotherapy (cohort 2). Primary outcome measures were objective response rate and overall survival. A matched-pair analysis was performed to compare overall survival to patients from the Tyrolean Lung Cancer Project as a historical control group. In total, 89 patients were identified, 42 patients in cohort 1 and 47 patients in cohort 2. The objective response rates were 43.3% and 31.4%, respectively. The median overall survival was 17.0 months (95% CI 11.7-21.5 months) in cohort 1 and 18.7 months (95% CI 9.5-23.4 months) in cohort 2. Treatment-related adverse events grades 3 and 4 were reported in 11.2% of patients. The matched-pair analysis showed a median overall survival of 15.2 months (95% CI 7.6-20.4 months) for first-line pembrolizumab monotherapy compared to 9.8 months (95% CI 7.8-11.6 months) for the historical control (p = 0.43). In cohort 2, a median overall survival of 20.3 months (95% CI 6.9-26.2 months) for second-line immunotherapy compared to 5.4 months (95% CI 3.2-11.7 months) for the historical control (p = 0.18) was shown. The results are comparable with other real-world studies and, when matched to historical controls, support the improvement in outcomes made possible by these agents.
Identifiants
pubmed: 34528126
doi: 10.1007/s00508-021-01940-w
pii: 10.1007/s00508-021-01940-w
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1122-1130Informations de copyright
© 2021. Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.
doi: 10.1056/NEJMoa1507643
Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
doi: 10.1056/NEJMoa1504627
Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.
doi: 10.1016/S0140-6736(15)01281-7
Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
doi: 10.1056/NEJMoa1606774
Reck M, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50 % or greater. J Clin Oncol. 2019;37(7):537–46.
doi: 10.1200/JCO.18.00149
Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.
doi: 10.1016/S0140-6736(16)32517-X
Berger ML, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health. 2017;20(8):1003–8.
doi: 10.1016/j.jval.2017.08.3019
Chan K, et al. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian real-world evidence for value of cancer drugs (CanREvalue) collaboration. BMJ Open. 2020;10(1):e32884.
doi: 10.1136/bmjopen-2019-032884
de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 2015;22(3):368–73.
doi: 10.14236/jhi.v22i3.177
Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304.
doi: 10.2147/JMDH.S160029
Lipworth W. Real-world data to generate evidence about healthcare interventions – the application of an ethics framework for big data in health and research. ABR. 2019;11:289. https://doi.org/10.1007/s41649-019-00095-1 .
doi: 10.1007/s41649-019-00095-1
pubmed: 33717317
pmcid: 7747250
Oyinlola JO, Campbell J, Kousoulis AA. Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res. 2016;16:299.
doi: 10.1186/s12913-016-1562-8
Goldstraw P, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.
doi: 10.1016/j.jtho.2015.09.009
CTEP. Common terminology criteria for adverse events (CTCAE). 2020. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm . Accessed 27 Jan 2020.
Seymour L, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e52.
doi: 10.1016/S1470-2045(17)30074-8
Kocher F, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Cancer Treat Res. 2015;87(2):193–200.
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
Wickham H. tidyverse: easily install and load the ‘Tidyverse’. R package version 1.2.1. 2017. https://CRAN.R-project.org/package=tidyverse .
Kassambara A, Kosinski M, Biecek P. survminer: drawing survival curves using ‘ggplot2’. R package version 0.4.6. 2019. https://CRAN.R-project.org/package=survminer . Accessed: 27 Jan 2020.
Dardis C. survMisc: miscellaneous functions for survival data. R package version 0.5.5. 2018. https://CRAN.R-project.org/package=survMisc . Accessed: 27 Jan 2020.
Planchard D, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):863–70.
doi: 10.1093/annonc/mdy474
Postmus PE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv1–iv21.
doi: 10.1093/annonc/mdx222
WCLC. Abstract OA14.01 – KEYNOTE-024 three-year survival update: pembrolizumab effective as first-line therapy for advanced non-small-cell lung cancer. 2019. https://www.iaslc.org/About-IASLC/News-Detail/keynote-024-three-year-survival-update-pembrolizumab-effective-as-first-line-therapy-for-advanced-nonsmall-cell-lung-cancer . Accessed 6 Feb 2020.
Mok TSK, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30.
doi: 10.1016/S0140-6736(18)32409-7
Faehling M, et al. Immuno-oncological treatment and tumor mass in non-small cell lung cancer: case-control analysis of overall survival in routine clinical practice. Oncology. 2019;97(4):228–35.
doi: 10.1159/000500885
Ahn BC, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD‑1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019;145(6):1613–23.
doi: 10.1007/s00432-019-02899-y
Areses Manrique MC, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018;7(3):404–15.
doi: 10.21037/tlcr.2018.04.03
Dudnik E, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Cancer Treat Res. 2018;126:217–23.
Juergens RA, et al. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol. 2018;25(6):384–92.
doi: 10.3747/co.25.4287
Khozin S, et al. Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval. Oncologist. 2019;24(5):648–56.
doi: 10.1634/theoncologist.2018-0307
Kobayashi K, et al. Real-world efficacy and safety of nivolumab for advanced non-small-cell lung cancer: a retrospective multicenter analysis. Clin Lung Cancer. 2018;19(3):e349–e58.
doi: 10.1016/j.cllc.2018.01.001
Martin C, et al. Efficacy and safety of nivolumab in previously treated patients with non-small-cell lung cancer: real world experience in Argentina. Clin Lung Cancer. 2020;21(5):e380–e7. https://doi.org/10.1016/j.cllc.2020.02.014 .
doi: 10.1016/j.cllc.2020.02.014
pubmed: 32213298
Mazieres J, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;24:24.
Merino Almazan M, et al. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice. Int J Clin Pharm. 2019;41(1):272–9.
doi: 10.1007/s11096-018-0772-z
Tambo Y, et al. Real-world efficacy of first-line pembrolizumab in patients with advanced or recurrent non-small-cell lung cancer and high PD-L1 tumor expression. Clin Lung Cancer. 2020;21(5):e366–e79. https://doi.org/10.1016/j.cllc.2020.02.017 .
doi: 10.1016/j.cllc.2020.02.017
pubmed: 32199806
Weis TM, et al. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy. J Oncol Pharm Pract. 2020;26(3):564–71.
doi: 10.1177/1078155219855127
Murteira R, et al. Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2020;29(10):1295–302. https://doi.org/10.1002/pds.5091 .
doi: 10.1002/pds.5091
pubmed: 32844487
Bjornhart B, et al. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol. 2019;58(7):953–61.
doi: 10.1080/0284186X.2019.1615636
Ksienski D, et al. Pembrolizumab for advanced nonsmall cell lung cancer: efficacy and safety in everyday clinical practice. Cancer Treat Res. 2019;133:110–6.
Tamiya M, et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50 % PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Invest New Drugs. 2019;37(6):1266–73.
doi: 10.1007/s10637-019-00843-y
Wang Y, et al. Treatment-related adverse events of PD‑1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–19.
doi: 10.1001/jamaoncol.2019.0393